Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.62 |
| ▸ | PLAU | P00749 | 2/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | F10 | P00742 | 1/20 | 0.59 |
| ▸ | PLAT | P00750 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330395 | 0.87 | TMPRSS4 (0.62) | PLAUF2F10PLATALOX15 | |
| SCHEMBL330512 | 0.87 | TMPRSS4 (0.62) | EGFRPLAUF2F10PLAT | |
| SCHEMBL467396 | 0.85 | P2RX1 (0.77) | HDAC3EGFRHDAC4HDAC1HDAC7 | |
| Bromochlorosalicylanilide SCHEMBL152257 | 0.85 | P2RX1 (0.77) | PLAUF2F10PLATALOX15 | |
| Dibromsalan SCHEMBL29496335 | 0.84 | PLAU (0.73) | EGFRPLAUF2F10PLAT | |
| Dibromsalan SCHEMBL646973 | 0.84 | PLAU (0.73) | EGFRPLAUF2F10PLAT | |
| SCHEMBL24460153 | 0.84 | TMPRSS4 (0.64) | HDAC3EGFRHDAC4HDAC1HDAC7 | |
| SCHEMBL30771726 | 0.84 | TMPRSS4 (0.64) | HDAC3EGFRHDAC4HDAC1HDAC7 | |
| SCHEMBL330383 | 0.84 | TMPRSS4 (0.77) | HDAC3EGFRHDAC4HDAC1HDAC7 | |
| SCHEMBL30771733 | 0.83 | P2RX1 (0.63) | HDAC3EGFRHDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005347-A4 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | SMITHKLINE BEECHAM CORP (US) | 2002-08-28 | — | — | EP | claimed |
| US-6255298-B1 | USING AN AROMATIC AMIDE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2001-07-03 | — | — | US | claimed |
| EP-1005347-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999007382-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-18 | — | — | WO | claimed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1005347-A4 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | SMITHKLINE BEECHAM CORP (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6255298-B1 | USING AN AROMATIC AMIDE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2001-07-03 | — | — | US | disclosed |
| EP-1005347-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999007382-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | HDAC3 168/4885EGFR 4368/4885HDAC4 524/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | HDAC3 57/4885EGFR 2680/4885HDAC4 230/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | HDAC3 57/4885EGFR 2825/4885HDAC4 211/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | HDAC3 57/4885EGFR 2825/4885HDAC4 211/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | HDAC3 57/4885EGFR 2825/4885HDAC4 211/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | HDAC3 65/4885EGFR 3119/4885HDAC4 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.